Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies

Michael Fossler, John Zhu, Claus Roehrborn, Paul McAleese, Michael Manyak

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background and Objectives: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. Methods: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0.5 mg soft gelatin capsule (marketed formulation, reference) versus a dutasteride 0.5 mg hard gelatin capsule and a dutasteride 0.5 mg tablet. The second assessed the relative bioavailability of dutasteride 0.5 mg from soft gelatin capsules containing 300 or 100 mg of mono- and diglycerides of caprylic acid/capric acid (MDC8, an emulsifying agent) versus the marketed formulation. Results: In the first study (n = 36), compared with the marketed soft gelatin capsule formulation, the bioavailability (least squares [LS] means ratio) of the tablet formulation was 76 % (90 % CI 0.68–0.84), and that of the hard gelatin capsule was 73 % (90 % CI 0.66–0.82). Peak exposures were also lower for the tablet (73 %; 90 % CI 0.66–0.81) and hard capsule (71 %; 90 % CI 0.64–0.79) relative to the marketed soft gelatin capsule. In the second study (n = 37), compared with the marketed soft gelatin formulation, the bioavailability (LS means ratio) of the 300 mg MDC8 capsule formulation was 95 % (90 % CI 0.88–1.03), and that of the 100 mg MDC8 capsule formulation was 93 % (90 % CI 0.86–1.00). Peak exposures were also lower for the 300 mg MDC8 (90 %; 90 % CI 0.81–0.99) and 100 mg MDC8 (87 %; 90 % CI 0.79–0.96) formulations. Conclusions: The bioavailability of, and peak exposure to, dutasteride are influenced by the formulation of the administered medication. These studies demonstrate the importance of formulation for obtaining the optimal pharmacokinetic properties of dutasteride.

Original languageEnglish (US)
Pages (from-to)763-767
Number of pages5
JournalClinical Drug Investigation
Volume36
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Capsules
Gelatin
Pharmacokinetics
Biological Availability
Tablets
tamsulosin
Least-Squares Analysis
Emulsifying Agents
Monoglycerides
Dutasteride
Diglycerides
Cross-Over Studies

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Impact of Formulation on the Pharmacokinetics of Dutasteride : Results from Two Phase I Studies. / Fossler, Michael; Zhu, John; Roehrborn, Claus; McAleese, Paul; Manyak, Michael.

In: Clinical Drug Investigation, Vol. 36, No. 9, 01.09.2016, p. 763-767.

Research output: Contribution to journalArticle

Fossler, Michael ; Zhu, John ; Roehrborn, Claus ; McAleese, Paul ; Manyak, Michael. / Impact of Formulation on the Pharmacokinetics of Dutasteride : Results from Two Phase I Studies. In: Clinical Drug Investigation. 2016 ; Vol. 36, No. 9. pp. 763-767.
@article{1a3a715cf09b436ebf863f8c17bfda1f,
title = "Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies",
abstract = "Background and Objectives: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. Methods: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0.5 mg soft gelatin capsule (marketed formulation, reference) versus a dutasteride 0.5 mg hard gelatin capsule and a dutasteride 0.5 mg tablet. The second assessed the relative bioavailability of dutasteride 0.5 mg from soft gelatin capsules containing 300 or 100 mg of mono- and diglycerides of caprylic acid/capric acid (MDC8, an emulsifying agent) versus the marketed formulation. Results: In the first study (n = 36), compared with the marketed soft gelatin capsule formulation, the bioavailability (least squares [LS] means ratio) of the tablet formulation was 76 {\%} (90 {\%} CI 0.68–0.84), and that of the hard gelatin capsule was 73 {\%} (90 {\%} CI 0.66–0.82). Peak exposures were also lower for the tablet (73 {\%}; 90 {\%} CI 0.66–0.81) and hard capsule (71 {\%}; 90 {\%} CI 0.64–0.79) relative to the marketed soft gelatin capsule. In the second study (n = 37), compared with the marketed soft gelatin formulation, the bioavailability (LS means ratio) of the 300 mg MDC8 capsule formulation was 95 {\%} (90 {\%} CI 0.88–1.03), and that of the 100 mg MDC8 capsule formulation was 93 {\%} (90 {\%} CI 0.86–1.00). Peak exposures were also lower for the 300 mg MDC8 (90 {\%}; 90 {\%} CI 0.81–0.99) and 100 mg MDC8 (87 {\%}; 90 {\%} CI 0.79–0.96) formulations. Conclusions: The bioavailability of, and peak exposure to, dutasteride are influenced by the formulation of the administered medication. These studies demonstrate the importance of formulation for obtaining the optimal pharmacokinetic properties of dutasteride.",
author = "Michael Fossler and John Zhu and Claus Roehrborn and Paul McAleese and Michael Manyak",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s40261-016-0419-6",
language = "English (US)",
volume = "36",
pages = "763--767",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "9",

}

TY - JOUR

T1 - Impact of Formulation on the Pharmacokinetics of Dutasteride

T2 - Results from Two Phase I Studies

AU - Fossler, Michael

AU - Zhu, John

AU - Roehrborn, Claus

AU - McAleese, Paul

AU - Manyak, Michael

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background and Objectives: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. Methods: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0.5 mg soft gelatin capsule (marketed formulation, reference) versus a dutasteride 0.5 mg hard gelatin capsule and a dutasteride 0.5 mg tablet. The second assessed the relative bioavailability of dutasteride 0.5 mg from soft gelatin capsules containing 300 or 100 mg of mono- and diglycerides of caprylic acid/capric acid (MDC8, an emulsifying agent) versus the marketed formulation. Results: In the first study (n = 36), compared with the marketed soft gelatin capsule formulation, the bioavailability (least squares [LS] means ratio) of the tablet formulation was 76 % (90 % CI 0.68–0.84), and that of the hard gelatin capsule was 73 % (90 % CI 0.66–0.82). Peak exposures were also lower for the tablet (73 %; 90 % CI 0.66–0.81) and hard capsule (71 %; 90 % CI 0.64–0.79) relative to the marketed soft gelatin capsule. In the second study (n = 37), compared with the marketed soft gelatin formulation, the bioavailability (LS means ratio) of the 300 mg MDC8 capsule formulation was 95 % (90 % CI 0.88–1.03), and that of the 100 mg MDC8 capsule formulation was 93 % (90 % CI 0.86–1.00). Peak exposures were also lower for the 300 mg MDC8 (90 %; 90 % CI 0.81–0.99) and 100 mg MDC8 (87 %; 90 % CI 0.79–0.96) formulations. Conclusions: The bioavailability of, and peak exposure to, dutasteride are influenced by the formulation of the administered medication. These studies demonstrate the importance of formulation for obtaining the optimal pharmacokinetic properties of dutasteride.

AB - Background and Objectives: Dutasteride is currently marketed by GlaxoSmithKline (GSK), either as monotherapy or as a fixed-dose combination with tamsulosin. As part of the project to develop the fixed-dose combination product, alternative formulations of dutasteride were prepared by GSK, and their pharmacokinetic properties were investigated. Methods: Two single-centre, open-label, active-comparator, randomised, three-period crossover studies were performed. The first study evaluated the relative bioavailability of dutasteride 0.5 mg soft gelatin capsule (marketed formulation, reference) versus a dutasteride 0.5 mg hard gelatin capsule and a dutasteride 0.5 mg tablet. The second assessed the relative bioavailability of dutasteride 0.5 mg from soft gelatin capsules containing 300 or 100 mg of mono- and diglycerides of caprylic acid/capric acid (MDC8, an emulsifying agent) versus the marketed formulation. Results: In the first study (n = 36), compared with the marketed soft gelatin capsule formulation, the bioavailability (least squares [LS] means ratio) of the tablet formulation was 76 % (90 % CI 0.68–0.84), and that of the hard gelatin capsule was 73 % (90 % CI 0.66–0.82). Peak exposures were also lower for the tablet (73 %; 90 % CI 0.66–0.81) and hard capsule (71 %; 90 % CI 0.64–0.79) relative to the marketed soft gelatin capsule. In the second study (n = 37), compared with the marketed soft gelatin formulation, the bioavailability (LS means ratio) of the 300 mg MDC8 capsule formulation was 95 % (90 % CI 0.88–1.03), and that of the 100 mg MDC8 capsule formulation was 93 % (90 % CI 0.86–1.00). Peak exposures were also lower for the 300 mg MDC8 (90 %; 90 % CI 0.81–0.99) and 100 mg MDC8 (87 %; 90 % CI 0.79–0.96) formulations. Conclusions: The bioavailability of, and peak exposure to, dutasteride are influenced by the formulation of the administered medication. These studies demonstrate the importance of formulation for obtaining the optimal pharmacokinetic properties of dutasteride.

UR - http://www.scopus.com/inward/record.url?scp=84976423769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976423769&partnerID=8YFLogxK

U2 - 10.1007/s40261-016-0419-6

DO - 10.1007/s40261-016-0419-6

M3 - Article

C2 - 27356530

AN - SCOPUS:84976423769

VL - 36

SP - 763

EP - 767

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 9

ER -